ArticleACS bio & med chem Au2026
A Picomolar MBP-Binding Nanobody for Target Enrichment and Modular Complex Engineering.
Article in ACS bio & med chem Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The variable domains of heavy chain only antibodies, also called nanobodies, have provided powerful new tools for biomedical research. Their rapid development across multiple fields has helped address emerging scientific and clinical challenges, establishing single-domain antibodies (sdAbs) as highly adaptable platforms for a wide range of biotechnological and therapeutic applications. In this study, we identified a nanobody from an alpaca immune library, sdAbCM1, that binds to the maltose-maltodextrin binding protein, MBP, with picomolar affinity. Biophysical investigations showed that sdAbCM1 recognizes a yet unreported epitope and interacts with MBP in its closed conformation when maltose is present. The high affinity, epitope specificity, and ability to tolerate the ligand-bound state render sdAbCM1 a valuable and versatile biotechnological tool with potential applications such as detection, localization, and purification of MBP fusion proteins and protein complex engineering for single-particle microscopy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.